by CytoPrevent | Jul 30, 2021 | Board’s Position Papers
Hazardous Drugs (HD) Task Force Leader For maximizing safety The handling of Hazardous medical drugs in a cancer treatment unit requires a specific approach in order to avoid unnecessary risks for the healthcare staff, and more particularly for the nurses. The...
by CytoPrevent | Jun 15, 2021 | Board’s Position Papers
Paris, June 10th, 2021 CytoPrevent* Advisory Board proposals to update the CMD While the European Commission has just started the Trilog process to amend the Carcinogen and Mutagen Directive (CMD), CytoPrevent Advisory Board wishes to express some key concerns...
by CytoPrevent | May 15, 2021 | Board’s Position Papers
The need to use a more appropriate acronym for CSTDs for administration of cytotoxic drugs Proposal for including in the amendment of Directive 2004/37/EC on the protection of workers from the risks related to exposure to carcinogens or mutagens at work, a...
by CytoPrevent | Apr 13, 2021 | Board’s Position Papers, News
ANNOUNCEMENT Paris, 13th April 2021 The CytoPrevent board strongly supports the European Parliament vote to include hazardous drugs and reprotoxics in the Carcinogens and Mutagens...
by CytoPrevent | Mar 5, 2021 | Board’s Position Papers, News
Dear Madam, Sir, CytoPrevent, a group of scientific experts, would like to use the opportunity to give our comments and suggestions on “work involving exposure to cytostatic agents”. We appreciate the appraisal as a step forward to improve worker’s safety and health...